Condition: Non-Small Cell Lung Cancer, NSCLC · KRAS, NRAS, HRAS-mutated NSCLC · KRAS G12C-mutated Solid Tumors, Lung Cancer · Sponsor: Revolution Medicines, Inc.
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
This description comes directly from the study's public registry record.
Revolution Medicines · 1-844-2-REVMED · medinfo@RevMed.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| City of Hope - Duarte | Duarte, California, United States | Recruiting |
| City of Hope - Lennar | Irvine, California, United States | Recruiting |
| UC Davis, Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| University of California, San Diego Moores Cancer Center | San Diego, California, United States | Recruiting |
| UCSF Medical Center - Mission Bay | San Francisco, California, United States | Recruiting |
| Stanford University - Stanford Cancer Institute | Stanford, California, United States | Recruiting |
| Colorado Health Medical Group - Medical Oncology & Hematology | Colorado Springs, Colorado, United States | Recruiting |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Boca Raton Clinical Research Associates | Plantation, Florida, United States | Recruiting |
| Cancer Specialists of North Florida | Saint Augustine, Florida, United States | Recruiting |
| H Lee Moffitt Cancer Center and Research Institute | Tampa, Florida, United States | Recruiting |
+ 81 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06162221